<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004017</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067235</org_study_id>
    <secondary_id>PEREGRINE-TNT9802</secondary_id>
    <secondary_id>MUSC-7993</secondary_id>
    <secondary_id>PEREGRINE-BB-IND-7344</secondary_id>
    <secondary_id>TCLONE-BB-IND-7344</secondary_id>
    <secondary_id>TCLONE-TNT9802</secondary_id>
    <secondary_id>NCI-G99-1560</secondary_id>
    <nct_id>NCT00004017</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma</brief_title>
  <official_title>Phase II Open-Label, Non-Randomized, Multicenter Study of Interstitial 131I-chTNT-1/B for the Treatment of Newly Diagnosed or Recurrent Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver&#xD;
      tumor-killing substances to them without harming normal cells. This may be an effective&#xD;
      treatment for some types of brain tumors.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of radiolabeled monoclonal antibody in&#xD;
      treating patients who have glioblastoma multiforme or anaplastic astrocytoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the median time to disease progression in patients with newly diagnosed&#xD;
           unresectable glioblastoma multiforme (GBM), recurrent GBM, or recurrent anaplastic&#xD;
           astrocytoma treated with interstitial iodine I 131 monoclonal antibody TNT-1/B.&#xD;
&#xD;
        -  Determine the median survival time of these patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in terms of neurotoxicity, renal, hepatic,&#xD;
           hematologic, and biochemical profiles in these patients.&#xD;
&#xD;
        -  Confirm the maximum tolerated dose of this regimen in these patients.&#xD;
&#xD;
        -  Optimize the drug delivery of this regimen in these patients.&#xD;
&#xD;
        -  Assess the response of these patients in terms of MRI measured gadolinium enhanced tumor&#xD;
           volume and gadolinium enhanced tumor area at 8 and 12 weeks following the last dose of&#xD;
           study drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo stereotactic implantation of 2 interstitial catheters into the tumor bed.&#xD;
      One day later, patients receive iodine I 131 monoclonal antibody TNT-1/B interstitially over&#xD;
      approximately 24 hours. At selected centers, up to 3 additional groups of 3 patients each&#xD;
      will receive study drug up to 48 hours. Catheters are removed 1 day after completion of the&#xD;
      infusion. A gadolinium enhanced MRI is performed during week 8. Patients with partial&#xD;
      response, minimal response, or stable disease repeat the above treatments during week 9.&#xD;
      Patients with complete response, progressive disease, or unacceptable toxicity receive no&#xD;
      additional treatment.&#xD;
&#xD;
      Patients are followed every month until disease progression. All patients regardless of&#xD;
      disease progression or retreatment are followed at 36 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (20 patients with newly diagnosed unresectable&#xD;
      glioblastoma multiforme [GBM]; 20 patients with recurrent GBM; and 20 patients with recurrent&#xD;
      anaplastic astrocytoma) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody TNT-1/B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed unresectable glioblastoma multiforme (GBM),&#xD;
             recurrent GBM, or recurrent anaplastic astrocytoma (AA)&#xD;
&#xD;
          -  MRI scan documenting gadolinium enhanced tumor volume of at least 5 cm3, but no&#xD;
             greater than 60 cm^3&#xD;
&#xD;
               -  Recurrent GBM and AA must be documented by MRI after the most recent treatment&#xD;
                  and before any planned surgical debulking&#xD;
&#xD;
          -  At least 5 days since prior surgical debulking&#xD;
&#xD;
          -  No planned resection of newly diagnosed GBM before or during study&#xD;
&#xD;
          -  No bilateral noncontiguous gadolinium enhancing tumors&#xD;
&#xD;
          -  No satellite lesions greater than 1.5 cm from anticipated location of interstitial&#xD;
             catheter tip&#xD;
&#xD;
          -  No more than 2 satellite lesions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase no greater than 3 times ULN&#xD;
&#xD;
          -  Prothrombin time no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant unstable cardiovascular disease&#xD;
&#xD;
          -  No New York Heart Association class III/IV heart disease&#xD;
&#xD;
          -  No evidence of myocardial infarction within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Human antichimeric antibody (HACA) titer no greater than 48 ng/mL&#xD;
&#xD;
          -  No anatomical or physiological considerations that would preclude study participation&#xD;
&#xD;
          -  No active autoimmune disease, active infection, or traumatic injury requiring&#xD;
             treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior intravenous chemotherapy or Gliadel wafers&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 8 weeks since prior external beam or gamma knife radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior investigational treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terrence G. Chew, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peregrine Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolina Neurosurgery and Spine Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207-1830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-0721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

